Brief: Active Biotech Announce Results In Arpeggio Phase II Trial With Laquinimod In Primary Progressive MS
01/12/2017 12:00
Dec 1 (Reuters) - Active Biotech AB ACTI.ST :
* ACTIVE BIOTECH ANNOUNCE RESULTS IN ARPEGGIO PHASE II TRIAL
WITH
LAQUINIMOD IN PRIMARY PROGRESSIVE MS
Source text for Eikon: ID:nGNXOJBNJa
Further company coverage: ACTI.ST
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million